Overall | Microscopic colitis | Non-microscopic colitis | p-value | |
---|---|---|---|---|

Interventions | ||||

Budesonide | 15/38 (39.5%) | 12/13 (92.3%) | 3/25 (12.0%) | < 0.001* |

Any systemic glucocorticoids | 25/38 (65.8%) | 3/13 (23.1%) | 22/25 (88.0%) | < 0.001* |

Systemic glucocorticoids < 1 mg/kg/d | 14/38 (36.8%) | 2/13 (15.4%) | 12/25 (48.0%) | 0.077 |

Systemic glucocorticoids ≥1 mg/kg/d | 12/38 (31.2%) | 1/13 (7.7%) | 11/25 (44.0%) | 0.030* |

Time from symptom onset to initiation of glucocorticoids (days) | ||||

Mean +/− SD | 32.4 +/− 37.1 | 33.2 +/− 26.0 | 32.0 +/− 42.7 | 0.928 |

Median | 21.0 | 28.0 | 18.0 | |

Proportion continuing CPI course | 14/38 (36.8%) | 10/13 (76.9%) | 4/25 (16.0%) | < 0.001* |

Proportion eventually discontinuing immunotherapy | 29/38 (76.3%) | 8/13 (61.5%) | 21/25 (84.0%) | 0.226 |

Due to toxicity alone | 22/38 (57.9%) | 6/13 (46.2%) | 16/25 (64.0%) | 1.000 |

Due to any progressive disease | 7/38 (18.4%) | 2/13 (15.4%) | 5/25 (25.0%) | |

Average number of additional infusions# | 3.0 +/− 5.7 | 5.8 +/− 6.8 | 1.6 +/− 4.5 | 0.030* |

Additional irAEs after colitis | 8/38 (21.1%) | 3/13 (23.1%) | 5/25 (20.0%) | 1.000 |

Response to first line treatment | 22/38 (67.9%) | 9/13 (69.2%) | 14/25 (56.0%) | 0.429 |

Proportion of patients requiring second-line immunosuppression | 23/38 (60.5%) | 5/13 (38.5%) | 18/25 (72.0%) | Not calculated |

Proportion requiring TNFα inhibitor | 16/38 (42.1%) | 4/13 (30.8%) | 11/25 (44.0%) | 0.429 |

The *p*-value was calculated by ANOVA for numerical covariates and chi-square test or Fisher’s exact for categorical covariates, where appropriate. TNFα: tumor necrosis factor α. CPI: immune checkpoint inhibitor. SD: standard deviation. irAE: immune-related adverse event. ^{#}calculated among patients who continued CPIs. *denotes statistical significance at *p* = 0.05. Second-line immune suppression includes exposure to different glucocorticoids in the microscopic colitis cohort

All of the boldfaced numbers should be statistically signficant